Drug intelligence / Profile preview

NA-LMWH

Development stage: Preclinical
Lead developer: Pfizer
Administration: Subcutaneous, Intravenous

Overview

NA-LMWH is a non-anticoagulant form of low-molecular-weight heparin (LMWH) designed to retain the anti-metastatic properties of LMWHs without their significant anticoagulant effects. It achieves its anti-metastatic action, in part, by promoting the release of endothelial tissue factor pathway inhibitor (TFPI). Unlike standard LMWHs such as enoxaparin, NA-LMWH does not significantly prolong clotting time or induce thrombocytopenia, making it a potential anti-metastatic agent with a reduced risk of bleeding complications.

Other names: non-anticoagulant low-molecular-weight heparin

Targets

HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))TFPI (Tissue factor pathway inhibitor)

Beyond the preview

Go deeper on NA-LMWH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NA-LMWH.

Explore the full profile